Anika Therapeutics, Inc. reports developments as a global joint preservation company focused on early intervention orthopedics. The company uses hyaluronic acid and implant solutions across Osteoarthritis Pain Management and Regenerative Solutions, with products and programs that include Monovisc, Orthovisc, Cingal, Hyalofast and the Integrity Implant System.
Recurring ANIK news includes quarterly and annual financial results, Commercial Channel and OEM Channel performance, gross margin and manufacturing execution, regulatory updates for orthopedic product programs, conference presentations, and governance changes. Company updates also address international OA pain management demand, regenerative product adoption, and operational initiatives tied to scaling production and portfolio advancement.
Anika Therapeutics, Inc. (NASDAQ: ANIK) announced plans to release its second quarter 2020 financial results on July 30, 2020, after market close. A conference call will follow at 5:00 p.m. ET to discuss these results along with business highlights and outlook. Investors can access the call through a toll-free number or an international line, and a live audio webcast will also be available on Anika's website. The presentation will be archived on the site post-event.
Anika Therapeutics (NASDAQ: ANIK) announces that CFO Sylvia Cheung will step down on August 21, 2020, after a transition period. The company is actively seeking her successor and may request Cheung to continue as a special advisor for a smooth transition. Cheung has been with Anika for 15 years, contributing significantly to the company's transformation strategy and finance functions. Both Cheung and CEO Cheryl R. Blanchard express confidence in Anika's future growth prospects.